Dihydrouracil Dehydrogenase (NADP)
"Dihydrouracil Dehydrogenase (NADP)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An oxidoreductase involved in pyrimidine base degradation. It catalyzes the catabolism of THYMINE; URACIL and the chemotherapeutic drug, 5-FLUOROURACIL.
| Descriptor ID |
D042943
|
| MeSH Number(s) |
D08.811.682.660.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dihydrouracil Dehydrogenase (NADP)".
Below are MeSH descriptors whose meaning is more specific than "Dihydrouracil Dehydrogenase (NADP)".
This graph shows the total number of publications written about "Dihydrouracil Dehydrogenase (NADP)" by people in this website by year, and whether "Dihydrouracil Dehydrogenase (NADP)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 2 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dihydrouracil Dehydrogenase (NADP)" by people in Profiles.
-
DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 05 20; 41(15):2701-2705.
-
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics. 2016 Mar; 26(3):133-7.
-
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci. 2006 Aug; 27(8):432-7.
-
The best of times...the worst of times. Eur J Cancer. 2003 Apr; 39(6):715-7.
-
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 2002 May; 8(5):1314; author reply 1315-6.
-
Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation. Clin Colorectal Cancer. 2002 May; 2(1):51-2.
-
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402.
-
Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet. 2000 Nov; 39(5):315-25.
-
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul; 9(7):1635-49.
-
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.